Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
Trump’s Chips War Has Left Intel’s New CEO With a Near-Impossible Task. Here’s Why and 5 Other Things to Know Today.
Cooler February inflation doesn’t mean Fed will lower rates, promising obesity drug could challenge Novo Nordisk and Eli ...
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Ignore the noise in GLP-1 stocks. Find the best value instead.
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
How to eat well with diabetes – and save money doing it
Miguel Barclay has built a reputation on proving that good food doesn’t need to cost more than £1 a portion. Now, he’s ...
Pfizer Remains A Good Pick For Dividend Investors
Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...
manilatimes14d
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...
NJBIZ16d
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group ...
MarketWatch16d
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...
Wall Street Journal17d
Novo Nordisk Stock Rises on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...